临床药师利用PDCA循环参与卵巢良性肿瘤临床路径管理的效果  

Effect of clinical pharmacists′participation in clinical pathway management of ovarian benign tumor by PDCA circulation

作　　者：钟媚共[1] 谭文锵[1] 伍卓坚 梁法亮[1] ZHONG Mei-gong;TAN Wen-qiang;WU Zhuo-jian;LIANG Fa-liang(Department of Pharmacy,Jiangmen Maternal and Child Health Hospital,Guangdong Province,Jiangmen529000,China)

机构地区：[1]广东省江门市妇幼保健院药学部,广东江门529000

出　　处：《中国当代医药》2020年第22期181-184,共4页China Modern Medicine

基　　金：广东省江门市医疗卫生科技计划项目(第四批)(2019D016)。

摘　　要：目的探讨临床药师利用PDCA循环参与卵巢良性肿瘤临床路径管理的方法和效果。方法选取我院2018年11月~2019年10月妇科收治的符合卵巢良性肿瘤临床路径入组标准的120例卵巢良性肿瘤住院患者,依据随机数字表法分为观察组和对照组,每组各60例。对照组实施常规卵巢良性肿瘤临床路径管理,观察组实施临床药师全程参的PDCA循环临床路径管理。观察组中,按照进行的循环周期不同分为观察1组与观察2组,各30例。观察1组进行第1个PDCA循环周期(2018年11月~2019年4月),观察2组进行第2个PDCA循环周期(2019年5~10月)。记录各组患者的费用情况、辅助用药情况、预防用抗菌药合理使用性以及复诊依从性。结果三组的住院时间比较,差异均无统计学意义(P>0.05);观察2组的住院费用低于观察1组和对照组,差异均有统计学意义(P<0.05);观察1组与对照组在住院费用方面差异无统计学意义(P>0.05);药品费用方面,对照组>观察1组>观察2组,组间比较差异均有统计学意义(P<0.05)。观察1组和观察2组的辅助用药费用和用药品种数少于对照组,差异均有统计学意义(P<0.05);且观察2组的辅助用药费用和用药品种数均少于观察1组,差异均有统计学意义(P<0.05)。观察1组和观察2组的抗菌药物使用合理率均高于对照组,差异均有统计学意义(P<0.05);观察2组复诊依从率高于对照组,差异有统计学意义(P<0.05);观察1组复诊依从率与对照组比较,差异无统计学意义(P>0.05);观察1组和观察2组的抗菌药物使用合理率、复诊依从率比较,差异无统计学意义(P>0.05)。结论以PDCA法来持续优化临床药师参与临床路径管理,能更好地规范临床用药,保障患者安全用药。第2个循环后住院费用、药品费用、辅助用药费用和用药品种数均得到进一步的优化,可见持续优化管理至关重要。Objective To explore the methods and effect of clinical pharmacists′participating in the clinical pathway management of ovarian benign tumors by PDCA circulation.Methods From November 2018 to October 2019,120 inpatients with ovarian benign tumor who met the criteria of clinical pathway of ovarian benign tumor were selected as the study objects,according to the method of random number table,they were divided into the observation group and the control group,60 cases in each group.The routine clinical pathway management of ovarian benign tumor was implemented in the control group,and the PDCA cycle clinical pathway management of clinical pharmacists was implemented in the observation group.The observation group was divided into the observation group 1 and the observation group 2 according to the different cycle,30 cases in the each group.The first PDCA cycle was implemented in the observation group 1(from November 2018 to April 2019),and the second PDCA cycle was implemented in the observation group 2(from May to October 2019).The cost condition,auxiliary medication condition,rational use of prophylactic antibiotics and follow-up compliance of patients in the each group were recorded.Results There was no statistically significant difference in the length of hospital stay among the three groups(P>0.05);the hospitalization cost of the observation group 2 was lower than that of the observation group 1 and the control group,and the differences were statistically significant(P<0.05);there was no statistically significant difference in hospitalization expenses between the observation group 1 and the control group(P>0.05);in terms of drug costs,the control group>observation 1 group>observation 2 groups,the differences among the three groups were statistically significant(P<0.05).Observation group 1 and observation group 2 had fewer auxiliary medication costs and medication varieties than the control group,and the differences were statistically significant(P<0.05);and observation 2 groups had fewer auxiliary medication co

关 键 词：临床药师 卵巢良性肿瘤 临床路径 PDCA循环法 

分 类 号：R197[医药卫生—卫生事业管理]